Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Celline C Almeida-BrasilJohn G HanlyMurray B UrowitzAnn Elaine ClarkeGuillermo Ruiz-IrastorzaCaroline GordonRosalind Ramsey-GoldmanMichelle A PetriEllen M GinzlerD J WallaceSang-Cheol BaeJuanita Romero-DiazMary Anne DooleyChristine PeschkenDavid Alan IsenbergAnisur RahmanSusan ManziSøren JacobsenSam LimRonald F Van VollenhovenOla NivedAndreas JönsenDiane L KamenCynthia AranowJorge Sanchez-GuerreroDafna D GladmanPaul R FortinGraciela S AlarconJoan T MerrillKenneth KalunianManuel Ramos-CasalsKristján SteinssonAsad ZomaAnca AskanaseMunther A KhamashtaIan N BruceMurat InançMichal AbrahamowiczSasha BernatskyPublished in: Annals of the rheumatic diseases (2021)
SLE flare risk was higher after HCQ taper/discontinuation versus HCQ maintenance. Decisions to maintain, reduce or stop HCQ may affect specific subgroups differently, including those on prednisone and/or with low education. Further study of special groups (eg, seniors) may be helpful.